We had the pleasure of meeting with Chia-Chun Chiang (Mayo Clinic, Rochester, MN, USA) to discuss a real world study of ubrogepant in participants with acute migraine.
The abstract entitled: ‘Real World Efficacy, Tolerability and Safety of Ubrogepant’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the current role of gepants in the treatment armamentarium for migraine? (0:30)
- What have clinical studies taught us about the efficacy and safety of ubrogepant? (1:57)
- Could you tell us a little about your real world study and its findings? (3:33)
- What factors were found to predict a good response to ubrogepant? (5:35)
Disclosures: Chia-Chun Chiang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Peter Goadsby, EAN 2023: Highlights in migraine
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a new potential biomarker of visual snow syndrome, and the second a presentation that he […]
Peter Goadsby, EAN 2023: Highlights in headache disorders
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of headache disorders. He highlights two important presentations using calcitonin gene-related peptide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!